DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multi-centre, prospective, observational cohort studyECCO '19 Copenhagen
2019
DOP64: Minimal additional benefits in adding faecal haemoglobin to faecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP65: The association of faecal calprotectin level and combined mucosal and transmural healing in patients with Crohn’s disease
ECCO '19 Copenhagen
2019
DOP66: Surveillance colonoscopies in ulcerative colitis: does it make a difference?
ECCO '19 Copenhagen
2019
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
DOP68: Histological remission (NANCY index) is superior to endoscopic mucosal healing in predicting relapse-free survival in patients with ulcerative colitis in clinical and endoscopic remission
ECCO '19 Copenhagen
2019
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
ECCO '19 Copenhagen
2019
DOP71: Effects of ustekinumab induction therapy on endoscopic and histological healing in the UNIFI Phase 3 study in ulcerative colitis
ECCO '19 Copenhagen
2019
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasia
ECCO '19 Copenhagen
2019
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton vs. anti-TNF vs. surgical closure following anti-TNF (PISA): a randomised controlled trial
ECCO '19 Copenhagen
2019
DOP74: Efficacy of ustekinumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
ECCO '19 Copenhagen
2019
DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015
ECCO '19 Copenhagen
2019
DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort
ECCO '19 Copenhagen
2019
DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease
ECCO '19 Copenhagen
2019
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
ECCO '19 Copenhagen
2019
DOP79: Effect of vedolizumab on surgical rates in IBD: post hoc analysis from the GEMINI trials
ECCO '19 Copenhagen
2019
DOP80: Oral curcumin is not more effective than placebo to prevent endoscopic postoperative recurrence in patients with Crohn's disease treated with concomitant thiopurines: the POPCUR trial
ECCO '19 Copenhagen
2019